Efficacy of influenza vaccine (Fluvax) in cancer patients on treatment: a prospective single arm, open-label study

ConclusionsPatients on various solid tumour treatments achieve sero-protection rate congruent with the general population. The sero-protection HIA titres were not sustained at 24  weeks postvaccination.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research

Related Links:

Respiratory infections can be caused by many viruses such as, influenza and coronavirus. If a novel virus gains the capacity to spread globally with sustained human-to-human transmission, a pandemic can occur (Qatar National Cancer Registry, 2014). Influenza epidemics are happening every year. In the past, several influenza pandemics have occurred such as, the 1918 pandemic (H1N1 virus), the 1957-1958 pandemic (H2N2 virus), 1968 pandemic (H3N2 virus), and the recent 2009 H1N1 pandemic (H1N1pdm09 virus) (Past Pandemics USA, 2018).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Review Source Type: research
Mark K. Slifka1* and Ian J. Amanna2 1Division of Neuroscience, Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, OR, United States2Najít Technologies, Inc., Beaverton, OR, United States Vaccines play a vital role in protecting our communities against infectious disease. Unfortunately, some vaccines provide only partial protection or in some cases vaccine-mediated immunity may wane rapidly, resulting in either increased susceptibility to that disease or a requirement for more booster vaccinations in order to maintain immunity above a protective level. The durability of a...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
The flu season is up and running in the Northern Hemisphere, and early signs in both the United States and Europe are that the effects might not be quite as severe as the brutal 2017/18 season. The United States is predominantly seeing H1N1 circulating, while monitoring in Europe has identified co-circulation of H1N1 and H3N2—both varieties of Influenza A that should be covered by the seasonable vaccine. What if they weren’t though? Influenza A can be found in both human and animal populations, and it evolves rapidly through genetic mutation. Each year many humans rely on their country&a...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news
Publication date: Available online 14 November 2018Source: PeptidesAuthor(s): Jun Xu, Shuo Chen, Jing Jin, Lingman Ma, Min Guo, Changlin Zhou, Jie DouAbstractInfluenza A virus is a leading cause of mortality in humans and poses a global health emergency due to its newly adapted and resistant strains. Thus, there is an urgency to develop novel anti-influenza drugs. Peptides are a type of biological molecule having a wide range of inhibitory effects against bacteria, fungi, viruses and cancer cells. The prospects of several peptides and their mechanisms of action have received significant attention. BF-30, a 30 amino acid re...
Source: Peptides - Category: Biochemistry Source Type: research
Conclusions: Patients with nonhematological malignancies who are receiving chemotherapy mount an immune response to influenza vaccination. Timing of influenza vaccination in relation to chemotherapy does not seem to matter.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Supportive Care Source Type: research
This study compared the immunogenicity of an influenza vaccine administered concurrently with chemotherapy (day 1) and within the cytopenic period (day 11) during 3‐week cytotoxic chemotherapy cycles. METHODSAdult patients with solid cancer undergoing scheduled 3‐week cytotoxic chemotherapy were randomly assigned to receive the 2014‐2015 seasonal influenza vaccine on day 1 or 11 during the chemotherapy cycle. Patients were stratified by their age (
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
Conclusion Despite low rate of response, flu and pneumococcal vaccines are worthwhile for patients with hematological malignancies. Patients undergoing chemotherapy in particular rituximab, splenectomy, transplant recipient had lower and impaired response. No serious adverse events were reported for both vaccines.
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Source Type: research
Objective Cancer patients receiving chemotherapy are at risk of acquiring influenza infections. Two-dose vaccination is a proposed strategy for increasing vaccination efficacy; however, this has yet to be confirmed in this population. The purpose of this study was to clarify the efficacy and safety of this strategy. Methods We conducted a multicentre prospective study on a two-dose vaccination regimen in cancer patients receiving chemotherapy. Second vaccinations were performed in patients who did not respond to all three viral strains after the first vaccination. Serum haemagglutination inhibition titres were measured to...
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Original article Source Type: research
Abstract Influenza is associated with significant morbidity and mortality in children receiving therapy for cancer, yet recommendation for, and uptake of the seasonal vaccine remains poor. One hundred children undergoing treatment for cancer were vaccinated with the trivalent inactivated influenza vaccine according to national guidelines in 2010 and 2011. Influenza‐specific hemagglutinin inhibition antibody titers were performed on blood samples taken prior to each vaccination and 4 weeks following the final vaccination. A nasopharyngeal aspirate for influenza was performed on all children who developed an influenza...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
by Christoph Jindra, Bettina Huber, Saeed Shafti-Keramat, Markus Wolschek, Boris Ferko, Thomas Muster, Sabine Brandt, Reinhard Kirnbauer Persistent infection with high-risk human papillomavirus (HPV) types, most often HPV16 and HPV18, causes all cervical and most anal cancers, and a subset of vulvar, vaginal, penile and oropharyngeal carcinomas. Two prophylactic virus-like particle (VLPs)-based vaccines, are available that protect against vaccine type-associated persistent infection and associated disease, yet have no therapeutic effect on existing lesions or infections. We have generated recombinant live-attenuated influ...
Source: PLoS One - Category: Biomedical Science Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | H1N1 | H3N2 | Influenza | Influenza Vaccine | Study | Swine Flu (H1N1) Vaccine | Vaccines